Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14686714 | 1.00 | MEN1 (0.37) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL5187861 | 0.89 | MEN1 (0.36) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL28325756 | 0.81 | KMT2A (0.39) | MEN1KMT2ASLC18A3SIGMAR1PRCP | |
| SCHEMBL28297380 | 0.81 | KCNH2 (0.37) | KMT2ASMN1; SMN2 | |
| SCHEMBL28568849 | 0.81 | KDM1A (0.40) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28574287 | 0.79 | KDM1A (0.41) | MEN1KMT2A | |
| SCHEMBL28565672 | 0.79 | HTR2C (0.46) | MEN1KMT2A | |
| SCHEMBL30014934 | 0.79 | KDM1A (0.41) | MEN1KMT2A | |
| SCHEMBL28325760 | 0.77 | DDB1 (0.42) | MEN1KMT2ASMN1; SMN2DDB1CRBN | |
| SCHEMBL28568767 | 0.76 | SLC18A3 (0.36) | MEN1KMT2ASLC18A3SIGMAR1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4178954-A1 | SUBSTITUTED PYRROLIDINE AMINES AND AMIDES AS MEDIATOR OF THE GLUCOCORTOID RECEPTOR | Grünenthal GmbH (DE) | 2023-05-17 | — | — | EP | claimed |
| CN-110372628-B | Internal sulfonamide compound and preparation method thereof | 武汉大学 | 2021-04-02 | — | — | CN | disclosed |
| CN-110372628-A | Interior sulfamide compound and preparation method thereof | 武汉大学 | 2019-10-25 | — | — | CN | disclosed |
| CN-106866574-B | A kind of method of reduction amination synthesis of chiral sulfanilamide (SN) in palladium chtalyst asymmetric molecult | 中国科学院大连化学物理研究所 | 2019-06-04 | — | — | CN | disclosed |
| EP-2565182-B1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-10-11 | — | — | EP | disclosed |
| US-8816079-B2 | Amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-26 | — | — | US | disclosed |
| EP-1498411-B9 | DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2013-12-04 | — | — | EP | disclosed |
| EP-2565182-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20130040930-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-02-14 | — | — | US | disclosed |
| EP-1498411-B1 | DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20040204368-A1 | Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-10-14 | — | — | US | disclosed |
| US-6797720-B2 | 1,3,4-oxadiazoline derivative and an agent comprising its derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| US-20030166574-A1 | 1,3,4-Oxadiazoline derivatives and drugs containing these derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| US-20030166573-A1 | Such as (2S)-N-((2S)-4-methyl-1-(5-(1-methylethylthio)1,3,4-oxadiazol-2-yl)-1-oxo-2 -pentyl)-2-benzyloxycarbonylamino-4-methylpentanamide for inhibition of cysteine proteases; antiinflammatory agents | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | NOKIA CORPORATION (FI) | 2003-08-28 | — | — | US | disclosed |
| US-20030153508-A1 | Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-08-14 | — | — | US | disclosed |
| EP-1254901-A1 | NITROGEN-CONTAINING 5-MEMBERED CYCLIC COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-1254898-A1 | BENZENE-FUSED HETEROCYCLE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-1234820-A1 | OXADIAZOLE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-28 | — | — | EP | disclosed |
| EP-1234821-A1 | 1,3,4-OXADIAZOLINE DERIVATIVES AND DRUGS CONTAINING THESE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204368-A1 | Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient | ACIN1, CASP3, CASP7 | MEN1 3321/4885KMT2A 4602/4885SLC18A3 2119/4885 |
| US-20130040930-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP2 | MEN1 2998/4885KMT2A 685/4885SLC18A3 4261/4885 |
| US-20030166574-A1 | 1,3,4-Oxadiazoline derivatives and drugs containing these derivatives as active ingredient | ACIN1, CASP7, SERPINE1 | MEN1 3814/4885KMT2A 3663/4885SLC18A3 3418/4885 |
| US-20030162964-A1 | Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient | BACH1, BACE1, CMA1 | MEN1 2086/4885KMT2A 4469/4885SLC18A3 2660/4885 |
| US-20030153508-A1 | Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient | ACIN1, CASP7, CASP10 | MEN1 1251/4885KMT2A 4457/4885SLC18A3 3510/4885 |
| US-20030166573-A1 | Such as (2S)-N-((2S)-4-methyl-1-(5-(1-methylethylthio)1,3,4-oxadiazol-2-yl)-1-oxo-2 -pentyl)-2-benzyloxycarbonylamino-4-methylpentanamide for inhibition of cysteine proteases; antiinflammatory agents | ACIN1, CASP7, ASNS | MEN1 3469/4885KMT2A 2023/4885SLC18A3 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.